This argument does not work.
”Cass said we don’t know if there are harms.”
That is being used backwards.
Cass did not say puberty blockers are safe. She said the evidence is weak and uncertain. In children’s medicine, uncertainty is not a green light. It is a reason for caution.
NHS England concluded there is not enough evidence to support the safety or clinical effectiveness of puberty blockers for children with gender incongruence/gender dysphoria. That is why they are not routinely available.
”There is no evidence of long-term harm.”
There is evidence of harm and evidence of serious risk.
NHS England states GnRHa may reduce the expected increase in lumbar or femoral bone density during puberty. That matters because puberty is when children build adult bone strength.
The Commission on Human Medicines advised there is currently an unacceptable safety risk in continued prescribing to children outside proper safeguards.
The FDA has also added warnings for GnRH agonists in children, including pseudotumor cerebri, also called idiopathic intracranial hypertension. Lupron Depot-Ped’s label also refers to psychiatric events, convulsions and other serious adverse reactions.
So no, these are not harmless pause buttons.
”If they were harmful, we’d see it in children treated for other conditions.”
We do see safety concerns in other uses. That is why paediatric GnRH agonist labels contain warnings.
But more importantly, this is a false comparison.
Central precocious puberty is a real, objective endocrine disorder: puberty starting abnormally early. The aim is to move development back towards normal timing.
Gender distress is completely different. In these children, puberty is not medically abnormal. The drug is being used to stop normal development because the child is distressed by it.
Different condition. Different purpose. Different ethics. Different risk-benefit calculation.
”The risks and benefits are unclear.”
Exactly. That is the problem.
You do not give powerful puberty-suppressing drugs to children on the basis that the risks and benefits are unclear. Especially not when the child is 11, distressed and cannot possibly understand future fertility, sexual development, bone health, brain development or lifelong medicalisation.
”But the trial will measure benefits.”
Measuring things is not the same as having a coherent positive outcome.
What is success?
If the child still has gender dysphoria, that is not success.
If the child goes from blockers to cross-sex hormones, that is not “time to think”. It is a pathway.
If the child feels temporarily better because normal puberty has been stopped, that proves nothing. An anorexic child may feel better if you help her avoid weight gain. That does not make it good medicine.
Puberty blockers do not and cannot solve gender dysphoria.
They cannot make a girl into a boy or a boy into a girl. They cannot make the body match the belief. They cannot resolve the underlying distress. They can only suppress healthy puberty.
The best outcome is that the child no longer has gender dysphoria and can live peacefully in their own body. Puberty blockers cannot produce that outcome.
So the real question is still unanswered: what good are these drugs supposed to do that careful, whole-child psychological support cannot do more safely?
Because if the answer is “stop puberty”, that is not treatment. That is the harm.